

## Conveniently Located in East Syracuse, Onondaga Hill & Auburn

Main Office Phone 315-472-7504 Nurse Navigator Phone 315-506-2469 Main Fax 315-634-5168

## Desmopressin (DDVAP/Stimate) Non-Oncology Treatment Order Set

2. DOB:	Height (inches):	Weight (lbs):
3. Diagnosis:		
[ ] Primary ICD-10 Code:	Diagnosis description:	
[ ] Other ICD-10 Code:	Diagnosis description:	
HOACNY will obtain authorization for drug admin	istration prior to scheduled infusion. If	HOACNY is unable to obtain insurance
authorization due to this medication not being in	alignment with the insurance plan's me	edical policy, referring office will be
notified and HOACNY will not be able to administ	er the medication.	
4. Pre-medications:		
[] Other Pre-medication:		
[] No Pre-medications indicated		
5. Drug Order:		
Desmopressin (DDAVP/Stimate) Ok to sub	ostitute with generic/biosimilar	
[] 0.3mcg/kg IV one time		
[] (1.5mg/ml concentration), 300mcg/50k	kg 1 spray each nostril	
[ ] Special Instructions:		
[] New to Therapy		
[] Continuing therapy: Last Dose Received	d Next Dose	Due
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reported	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluatio	on & management. The prescribing physici
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu.  [] Other:	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluation & complications associated with drug admination esion Referral	o condition or delayed adverse events that in & management. The prescribing physicionistration as well as drug specific monitori
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reported responsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infusion to the content of the content	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluation & complications associated with drug admination esion Referral	n condition or delayed adverse events that on & management. The prescribing physicion inistration as well as drug specific monitorion
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu. [] Other:  [] No lab monitoring indicated  HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FO The prescribing physician is responsible for ordering, obordered above.  7. Required Baseline Lab/Testing completed:  [] CBC, date: [] CM	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluation & complications associated with drug admission Referral asion  OR INFUSION ADMINISTRATION. btaining, reviewing all laboratory results & [ ] Factor VIII activity.	o condition or delayed adverse events that on & management. The prescribing physicion in the prescribing physicion in the prescribing physicion in the prescribing physicion in the prescribing as well as drug specific monitoring to the providing copy to HOACNY prior to infusion
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu. [] Other:  [] No lab monitoring indicated  HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FO The prescribing physician is responsible for ordering, of ordered above.  7. Required Baseline Lab/Testing completed:	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluation & complications associated with drug admission Referral asion  OR INFUSION ADMINISTRATION. btaining, reviewing all laboratory results & [ ] Factor VIII activity.	ty level, date:
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu. [] Other:  [] No lab monitoring indicated  HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FO The prescribing physician is responsible for ordering, obordered above.  7. Required Baseline Lab/Testing completed:  [] CBC, date: [] CM  [] VonWillebrand Factor, date: [] CM	licy & Procedure Guidelines. Any changes in the death of the prescribing physician for evaluation accomplications associated with drug admission Referral  Ission  OR INFUSION ADMINISTRATION.  Institution bit and in the death of the death o	ty level, date:
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu. [] Other:  [] No lab monitoring indicated  HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FO The prescribing physician is responsible for ordering, obordered above.  7. Required Baseline Lab/Testing completed:  [] CBC, date: [] CM  [] VonWillebrand Factor, date: [] CM	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluation & complications associated with drug adminision Referral  Ision  OR INFUSION ADMINISTRATION.  Instaining, reviewing all laboratory results & procedure in the process of t	condition or delayed adverse events that on & management. The prescribing physicion in the prescribing
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu. [] Other:  [] No lab monitoring indicated  HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FO The prescribing physician is responsible for ordering, obordered above.  7. Required Baseline Lab/Testing completed:  [] CBC, date: [] CM [] VonWillebrand Factor, date:	licy & Procedure Guidelines. Any changes in the death of the prescribing physician for evaluation and the complications associated with drug administration referral sistence.  BR INFUSION ADMINISTRATION. betaining, reviewing all laboratory results & section [] Factor VIII activity [] Other: program. (Program. (Program. (Program.)	ty level, date:
hypersensitivity reactions per the HOACNY Infusion Poloccur after leaving the infusion center are to be reporteresponsible for educating the patient of potential risks parameters before proceeding with Non-Oncology Infu.  6. Infusion Lab Requirements:  [] CBC & CMP within 30 days prior to infu. [] Other:  [] No lab monitoring indicated  HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FO The prescribing physician is responsible for ordering, obordered above.  7. Required Baseline Lab/Testing completed:  [] CBC, date: [] CM  [] VonWillebrand Factor, date:  8. Patient Assistance & REMS Program Enrolling [] Yes, patient has been enrolled in	licy & Procedure Guidelines. Any changes in ed to the prescribing physician for evaluation & complications associated with drug administration Referral  Ision  OR INFUSION ADMINISTRATION.  Instaining, reviewing all laboratory results & program. (Programs.)	condition or delayed adverse events that on & management. The prescribing physicic inistration as well as drug specific monitorial providing copy to HOACNY prior to infusion ty level, date:

(This drug administration order form is valid for 12 months)